What is the AJCC TNM staging for colon cancer and the recommended treatment for each stage?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 20, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

AJCC TNM Staging for Colon Cancer and Stage-Specific Treatment

Colon cancer is staged using the AJCC TNM system, with surgical resection as primary treatment for stages 0–III, mandatory adjuvant chemotherapy for all stage III disease, selective chemotherapy for high-risk stage II, and systemic therapy ± metastasectomy for stage IV. 1

TNM Classification System

Primary Tumor (T Stage)

  • Tis – carcinoma in situ confined to the mucosal lamina propria without invasion through the muscularis mucosae 2
  • T1 – tumor invades the submucosa 2
  • T2 – tumor invades the muscularis propria 2
  • T3 – tumor extends through the muscularis propria into the subserosa or non-peritonealized pericolic tissue 2
  • T4a – tumor perforates the visceral peritoneum 2
  • T4b – tumor directly invades adjacent organs or structures 2

Regional Lymph Node (N Stage)

  • N0 – no regional lymph node metastasis 2
  • N1a – metastasis in 1 regional lymph node 2
  • N1b – metastasis in 2–3 regional lymph nodes 2
  • N1c – tumor deposits in the subserosa or pericolic soft tissue without any positive lymph nodes 2
  • N2a – metastasis in 4–6 regional lymph nodes 2
  • N2b – metastasis in 7 or more regional lymph nodes 2

Critical pitfall: N1c is applied only when tumor deposits are present and no lymph nodes are positive; if any nodes are positive, staging follows the number-based N categories. 2

Distant Metastasis (M Stage)

  • M0 – no distant metastasis 2
  • M1a – metastasis confined to a single organ (liver, lung, ovary, non-regional lymph nodes) without peritoneal involvement 2
  • M1b – metastasis in more than one organ 2
  • M1c – peritoneal metastasis, with or without involvement of other organs 2

Overall Stage Groupings and 5-Year Survival

Stage TNM Combination 5-Year Survival
0 Tis N0 M0 —
I T1-2 N0 M0 ~93% [1]
IIA T3 N0 M0 ~85% [1]
IIB T4a N0 M0 ~72% [1]
IIC T4b N0 M0 —
IIIA T1-2 N1/N1c M0 or T1 N2a M0 ~83% [1]
IIIB T3-4a N1/N1c M0 or T2-3 N2a M0 or T1-2 N2b M0 ~64% [1]
IIIC T4a N2a M0 or T3-4a N2b M0 or T4b N1-2 M0 ~44% [1]
IV Any T Any N M1 ~8% [1]

Pathological Requirements for Accurate Staging

  • Examination of at least 12 regional lymph nodes is mandatory to reliably stage colon cancer and avoid understaging; fewer nodes constitute a quality failure and may lead to omission of necessary adjuvant chemotherapy. 1, 2
  • Mandatory pathological descriptors include: 1, 2
    • Circumferential resection margin (CRM) status
    • Vascular invasion (lymphatic and venous)
    • Perineural invasion
    • Histologic grade
    • Tumor deposits (if present)

Treatment Recommendations by Stage

Stage 0 (Tis N0 M0)

  • Local excision (polypectomy) is sufficient for carcinoma in situ. 1

Stage I (T1-2 N0 M0)

For T1 tumors:

  • Wide surgical resection after R0 polypectomy is not necessary for low-risk T1 carcinomas (G1 or G2, no lymphatic invasion, margins ≥1 mm) because the lymph node metastasis rate is <4%. 1
  • Standard resection should follow for higher-risk T1 tumors (grading >2, invasion of submucosa, lymphatic or venous invasion, resection margins <1 mm, tumor budding, or invasive carcinoma in a sessile polyp), even after definite R0 removal. 1

For T2 tumors:

  • Wide surgical resection with at least 5 cm margins on either side of the tumor and removal of lymphatic drainage with at least 12 lymph nodes is required. 1, 3
  • No adjuvant chemotherapy is indicated. 3

Stage II (T3-4 N0 M0)

Surgical treatment:

  • Wide surgical resection with at least 5 cm margins and removal of at least 12 lymph nodes is required. 1, 3

Adjuvant chemotherapy decision algorithm:

  1. Verify adequate staging: Confirm ≥12 lymph nodes were examined. 4
  2. Test for MSI/MMR status: Perform mismatch repair deficiency (dMMR) or microsatellite instability (MSI-H) testing. 4
  3. Assess risk factors: 4
    • High-risk features include: T4 tumors (stage IIB/IIC), <12 lymph nodes examined, poorly/undifferentiated histology, lymphovascular invasion, perineural invasion, intestinal obstruction, tumor perforation, grade BD3 tumor budding (≥10 buds)

Treatment by risk category:

  • Low-risk stage IIA (T3, ≥12 nodes, no high-risk features):

    • Surgery alone is recommended; adjuvant chemotherapy is discouraged because harms outweigh benefits in unselected populations. 4

  • High-risk stage II (≥1 high-risk feature, MSS/pMMR):

    • Fluoropyrimidine monotherapy (capecitabine or infusional 5-FU/leucovorin) for 6 months may be offered after thorough discussion of modest absolute survival benefit (<5% at 5 years) versus toxicity. 4
    • Oxaliplatin should NOT be added routinely to stage II disease, even with high-risk features, due to lack of overall survival benefit and increased peripheral neuropathy risk. 4

  • MSI-high/dMMR tumors:

    • Fluoropyrimidine-based chemotherapy should NOT be routinely offered because these tumors have better prognosis and derive little benefit. 4

Stage III (Any T N1-2 M0)

Surgical treatment:

  • Wide surgical resection with at least 5 cm margins and removal of at least 12 lymph nodes is required. 1, 3

Adjuvant chemotherapy:

  • Adjuvant chemotherapy is mandatory for all stage III colon cancer patients following complete resection. 3, 4
  • FOLFOX (5-FU/leucovorin/oxaliplatin) or XELOX (capecitabine/oxaliplatin) for 6 months is the standard treatment, providing approximately 15% absolute survival benefit. 4
  • Modified FOLFOX6 is preferred over FLOX due to better toxicity profile. 4
  • XELOX is equally effective and avoids central venous catheter complications. 4
  • If oxaliplatin is contraindicated, use fluoropyrimidine monotherapy (capecitabine or infusional 5-FU/leucovorin). 4
  • Start adjuvant chemotherapy within 6–8 weeks of surgery, ideally as soon as the patient has recovered from surgical complications. 4

Stage IV (Any T Any N M1)

Treatment approach:

  • Upfront systemic chemotherapy is the primary treatment. 1
  • Resection of primary tumor and metastases (simultaneous or delayed) should be pursued if resectability is achieved. 1
  • KRAS genotyping of tumor tissue (primary tumor or metastasis) is strongly recommended at diagnosis to plan for the treatment continuum, as KRAS mutations predict lack of response to cetuximab or panitumumab therapy. 1

Preoperative Staging Evaluation

  • Minimal requirements for distant staging: CT of chest and abdomen, complete colonoscopy (pre- or postoperatively), physical examination, medical and family history of colorectal cancer, polyps, and other cancers. 1
  • CEA should be determined before treatment. 1
  • FDG-PET is not recommended for initial staging. 1
  • Bone scan and brain imaging should be performed only for patients with related symptoms. 1

Common Pitfalls to Avoid

  • Do not offer adjuvant chemotherapy to unselected stage II patients without first confirming high-risk features; potential harms outweigh benefits. 4
  • Do not add oxaliplatin routinely to stage II disease, even with high-risk features; it provides no proven survival advantage. 4
  • Do not omit MSI/MMR testing before deciding on adjuvant therapy, as dMMR changes the treatment approach. 4
  • Do not accept inadequate lymph node sampling (<12 nodes) as it leads to understaging and inappropriate treatment decisions. 1, 2
  • Age alone should NOT alter treatment recommendations—elderly patients tolerate capecitabine well, and younger low-risk patients should not receive chemotherapy based solely on age. 4

References

1
Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

2
Guideline

TNM Staging and Pathological Assessment for Sigmoid Colon Adenocarcinoma

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

3
Guideline

Colorectal Cancer Staging and Treatment Approach

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

4
Guideline

Adjuvant Chemotherapy for Colon Cancer

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Related Questions

What is the staging of colon cancer in a patient?
What is the significance of staging in a patient with colon cancer, particularly in determining the need for adjuvant chemotherapy?
What is the TNM (Tumor, Node, Metastasis) staging system for colorectal cancer?
What is the TNM staging system for primary sigmoid colon adenocarcinoma, including T, N, M categories and stage groupings?
A patient taking losartan twice daily continues to have blood pressure spikes; what is the appropriate next step in managing his hypertension?
What is the safest way to transition a patient stabilized on long‑acting injectable aripiprazole lauroxil (Aristada) to oral ziprasidone (Geodon)?
What is the immediate next step in management for an oncologic patient with a colostomy, recent unsuccessful colonoscopy, sudden epigastric and lumbar pain refractory to metamizole and tramadol, and a normal electrocardiogram?
When can a hospitalized colitis patient be safely discharged based on stable vital signs, afebrile status, tolerance of oral intake, resolution of diarrhea or bleeding, improving laboratory values, no need for intravenous therapy, and a reliable outpatient follow‑up plan?
What is the recommended treatment regimen for Trichomonas vaginalis infection in men?
In a patient with end‑stage renal disease on regular hemodialysis, is nifedipine removed by hemodialysis?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question